Co-Diagnostics, Inc. Set to Engage with Investors at 2025 Maxim Growth Summit

Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit

Co-Diagnostics, Inc. (Nasdaq: CODX), a pioneering firm in molecular diagnostics, will be taking part in the upcoming 2025 Maxim Growth Summit. Scheduled for October 22-23, the summit will be held at the iconic Hard Rock Hotel in New York City. This esteemed event draws a multitude of industry leaders, innovators, and key institutions, making it a significant platform for discussing the latest trends and advancements in numerous sectors.

Highlighting the summit's agenda are distinguished keynote speakers, including Larry Kudlow, a prominent broadcaster for Fox News, and Christopher Ruddy, CEO of Newsmax Media. Attendees can expect to engage in in-depth roundtable discussions, led by Maxim Research Analysts, featuring CEOs from emerging small to mid-cap companies. Conversations will touch upon a vast array of fields, such as biotechnology, stem cell therapies, artificial intelligence, energy and mining sectors, as well as the burgeoning drone industry.

Co-Diagnostics plans to maximize its presence at the summit by meeting with institutional investors in a one-on-one format, presenting a unique opportunity to discuss its innovations and market potential. Furthermore, senior analysts from Maxim will be present, facilitating insightful dialogue about Co-Diagnostics' future directions and investment possibilities.

For those interested in understanding the full agenda of the Maxim Growth Summit, detailed information can be found on their official website at www.maximgrp.com/2025-growth-summit.

About Maxim Group LLC

Maxim Group LLC operates as a comprehensive investment banking, securities, and wealth management firm based in New York. This independent, employee-owned company provides a broad range of financial services, including private wealth management and trading in equities, fixed income, and derivatives. As a registered broker-dealer with the Securities and Exchange Commission and a member of FINRA, SIPC, and NASDAQ, Maxim Group is well-positioned to serve diverse financial needs. For more info, visit maximgrop.com.

About Co-Diagnostics, Inc.

Based in Utah, Co-Diagnostics, Inc. specializes in cutting-edge molecular diagnostics technology. Their expertise lies in developing, manufacturing, and marketing innovative diagnostic tools that detect and analyze nucleic acid molecules such as DNA or RNA. The company’s proprietary technology is also utilized for specific tests for its Co-Dx PCR home and point-of-care platforms, which are currently under regulatory review and not yet available for sale. These advancements aim to identify genetic markers for applications beyond infectious disease detection, showcasing Co-Diagnostics’ commitment to improving global health through innovation and technology.

As they prepare for the Maxim Growth Summit, Co-Diagnostics continues to position itself as a leader in the molecular diagnostics field, promising exciting developments ahead for both the company and its investors.